Publications by authors named "J Mossong"
Article Synopsis
- 45.9% of reported HIV cases were in migrants, with the majority (86.7%) coming from non-EU/EEA countries.
- A concerning 52.4% of migrants received a late HIV diagnosis, especially non-EU/EEA migrants through heterosexual transmission, highlighting the need for better prevention and testing strategies.
Background: The COVID-19 vaccination campaign in several European countries involved collaboration between public health and Primary Health Care (PHC).
Objective: To highlight the role of PHC professionals in the COVID-19 vaccination rollout, specifically in terms of vaccine administration, communication and contributing to vaccination population coverage.
Methods: A descriptive retrospective study of the COVID-19 vaccination campaign across 28 European countries was conducted, covering data from December 2020 to November 2021.
Background: By March, 2023, 54 countries, areas, and territories (hereafter CAT) in the WHO European Region had reported more than 2·2 million COVID-19-related deaths to the WHO Regional Office for Europe. Here, we estimated how many lives were directly saved by vaccinating adults in the WHO European Region from December, 2020, to March, 2023.
Methods: In this retrospective surveillance study, we estimated the number of lives directly saved by age group, vaccine dose, and circulating variant-of-concern (VOC) period, regionally and nationally, using weekly data on COVID-19 mortality and infection, COVID-19 vaccination uptake, and SARS-CoV-2 virus characterisations by lineage downloaded from The European Surveillance System on June 11, 2023, as well as vaccine effectiveness data from the literature.
Background: Luxembourg experienced major consecutive SARS-CoV-2 infection waves due to Omicron variants during 2022 while having achieved a high vaccination coverage in 2021. We investigated the risk factors associated to severe outcomes (i.e.
View Article and Find Full Text PDFArticle Synopsis
- Luxembourg's introduction of nirsevimab immunisation for RSV led to an impressive neonatal coverage of 84% in 2023.
- The number of paediatric RSV-related hospitalisations for infants under 6 months significantly decreased, dropping from 232 in 2022 to 72 in 2023.
- Additionally, hospital stays shortened and the average age of hospitalised children increased, indicating that nirsevimab effectively reduced severe RSV infections and lessened the burden on healthcare.